FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579173834> ?p ?o ?g. }

• W2579173834 abstract "Abstract Background: The beneficial effect of adding rituximab to CHOP has been shown for elderly patients with DLBCL (Coiffier et al, N.E.J.M 2002). We have shown that HDT with autologous stem cell transplantation is superior to CHOP in young adults with DLCL ( Milpied et al GOELAMS 072 trial, N.E.J.M 2004). The feasibility of adding rituximab to front-line HDT remains to be established. Methods: A prospective pilot trial was proposed to patients with DLBCL, with intermediate-high or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose CHOP-like regimen, 15 days apart, with rituximab (375/mg/m2) on day 1 of each course, followed by rituximab on d 22, harvest of G-CSF mobilised peripheral blood stem cells on d 28,29, then rituximab on d 36 followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR after these 3 courses, a BEAM regimen started on d 66 to 80 followed by the infusion of stem cells. Results: Between 04/2002 and 05/2003, 42 pts gave their informed consent and were included in that trial. Median age was 50 y.o (18–60 y.o), 23 had WHO PS ≥ 2, the LDH level was >N in 41 pts and 38 had stage III or IV disease. The age-adjusted IPI was intermediate-high in 23 and high in 19 pts. The program was completed in 30 pts (71%), 3 pts died of toxicity before the BEAM regimen, 8 pts failed to achieve at least a PR after the first 3 courses and 1 refused the autologous transplant. On an intent-to-treat basis, the response rate at the end of the treatment was CR/Cru=64%, PR=7%, less than PR or progression= 22% and toxic death=7%. No toxic death was directly attributable to the addition of rituximab. With a median FU of 19 m, the KM 2y probability of OS and EFS are 79% and 59% respectively, these figures compare to those achieved without rituximab in the previous trial as shown on the table: Conclusion : The addition of 4 doses of rituximab to this HDT program is feasible with no unexpected toxicity, allows the harvesting of sufficient numbers of stem cells to support an autologous transplant with a BEAM regimen in responding patients. This treatment is now being randomly prospectively compared with CHOP-14-rituximab in youg adults with DLBCL (Goelams 075 trial).Supported in part by Roche which kindly provided rituximab for that trial and by DRC Nantes programme N°:02/2N 2002. GOELAMS 072 (IPI 2 only) GOELAMS 074 (IPI 2–3) 2y OS 80% 79% 2y EFS 60% 59%" @default.
• W2579173834 created "2017-01-26" @default.
• W2579173834 creator A5004069143 @default.
• W2579173834 creator A5007764355 @default.
• W2579173834 creator A5014982413 @default.
• W2579173834 creator A5035139653 @default.
• W2579173834 creator A5041108107 @default.
• W2579173834 creator A5045374333 @default.
• W2579173834 creator A5052071966 @default.
• W2579173834 creator A5056150288 @default.
• W2579173834 creator A5058751095 @default.
• W2579173834 creator A5074402846 @default.
• W2579173834 creator A5085944020 @default.
• W2579173834 creator A5086814640 @default.
• W2579173834 creator A5088580473 @default.
• W2579173834 date "2004-11-16" @default.
• W2579173834 modified "2023-10-01" @default.
• W2579173834 title "Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL) : Goelams 074 Trial." @default.
• W2579173834 doi "https://doi.org/10.1182/blood.v104.11.902.902" @default.
• W2579173834 hasPublicationYear "2004" @default.
• W2579173834 type Work @default.
• W2579173834 sameAs 2579173834 @default.
• W2579173834 citedByCount "2" @default.
• W2579173834 crossrefType "journal-article" @default.
• W2579173834 hasAuthorship W2579173834A5004069143 @default.
• W2579173834 hasAuthorship W2579173834A5007764355 @default.
• W2579173834 hasAuthorship W2579173834A5014982413 @default.
• W2579173834 hasAuthorship W2579173834A5035139653 @default.
• W2579173834 hasAuthorship W2579173834A5041108107 @default.
• W2579173834 hasAuthorship W2579173834A5045374333 @default.
• W2579173834 hasAuthorship W2579173834A5052071966 @default.
• W2579173834 hasAuthorship W2579173834A5056150288 @default.
• W2579173834 hasAuthorship W2579173834A5058751095 @default.
• W2579173834 hasAuthorship W2579173834A5074402846 @default.
• W2579173834 hasAuthorship W2579173834A5085944020 @default.
• W2579173834 hasAuthorship W2579173834A5086814640 @default.
• W2579173834 hasAuthorship W2579173834A5088580473 @default.
• W2579173834 hasConcept C126322002 @default.
• W2579173834 hasConcept C141071460 @default.
• W2579173834 hasConcept C143998085 @default.
• W2579173834 hasConcept C2776694085 @default.
• W2579173834 hasConcept C2778336483 @default.
• W2579173834 hasConcept C2778559949 @default.
• W2579173834 hasConcept C2779050716 @default.
• W2579173834 hasConcept C2779338263 @default.
• W2579173834 hasConcept C2779725641 @default.
• W2579173834 hasConcept C2780653079 @default.
• W2579173834 hasConcept C2781413609 @default.
• W2579173834 hasConcept C2911091166 @default.
• W2579173834 hasConcept C71924100 @default.
• W2579173834 hasConcept C90924648 @default.
• W2579173834 hasConceptScore W2579173834C126322002 @default.
• W2579173834 hasConceptScore W2579173834C141071460 @default.
• W2579173834 hasConceptScore W2579173834C143998085 @default.
• W2579173834 hasConceptScore W2579173834C2776694085 @default.
• W2579173834 hasConceptScore W2579173834C2778336483 @default.
• W2579173834 hasConceptScore W2579173834C2778559949 @default.
• W2579173834 hasConceptScore W2579173834C2779050716 @default.
• W2579173834 hasConceptScore W2579173834C2779338263 @default.
• W2579173834 hasConceptScore W2579173834C2779725641 @default.
• W2579173834 hasConceptScore W2579173834C2780653079 @default.
• W2579173834 hasConceptScore W2579173834C2781413609 @default.
• W2579173834 hasConceptScore W2579173834C2911091166 @default.
• W2579173834 hasConceptScore W2579173834C71924100 @default.
• W2579173834 hasConceptScore W2579173834C90924648 @default.
• W2579173834 hasLocation W25791738341 @default.
• W2579173834 hasOpenAccess W2579173834 @default.
• W2579173834 hasPrimaryLocation W25791738341 @default.
• W2579173834 hasRelatedWork W199790948 @default.
• W2579173834 hasRelatedWork W2247122458 @default.
• W2579173834 hasRelatedWork W2400119370 @default.
• W2579173834 hasRelatedWork W2557210801 @default.
• W2579173834 hasRelatedWork W2563179174 @default.
• W2579173834 hasRelatedWork W2579173834 @default.
• W2579173834 hasRelatedWork W2587933464 @default.
• W2579173834 hasRelatedWork W2588498504 @default.
• W2579173834 hasRelatedWork W2978307598 @default.
• W2579173834 hasRelatedWork W2979864420 @default.
• W2579173834 isParatext "false" @default.
• W2579173834 isRetracted "false" @default.
• W2579173834 magId "2579173834" @default.
• W2579173834 workType "article" @default.